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Introduction
Like many other potentially catastrophic events for which govern-
ments need to prepare, influenza pandemics are rare. Although 
the risk is considered to be 3–4% per annum1, the public health 
consequences are widely recognised to be potentially severe2. The 
epidemiology of only a small number of influenza pandemics 
has been well studied and evidence for the effectiveness of reme-
dial influenza treatments in a pandemic scenario is scant. Yet, 
governments around the world still have to decide whether or 
not to stockpile anti-influenza medication like neuraminidase 
inhibitor (NAI) antivirals, such as oseltamivir (Tamiflu®) and 
zanamivir (Relenza®), as a defence against pandemic influenza.
The stockpiling of NAIs has been a controversial issue. Firstly, 
stockpiling may be seen to be a waste of large amounts of public 
money if the pandemic fails to materialise or if it is mild. In the 
United Kingdom, the previous Chief Medical Officer was criticised 
for spending £560 million on medicine that went largely unused in 
the 2009–10 pandemic3. However, taking a default position of not 
stockpiling, or making the decision on the basis of intuition alone, is 
not justifiable given the rare but potentially catastrophic losses asso-
ciated with pandemic influenza and the large cost of stockpiling.
Secondly, there has been a lack of conclusive evidence on the 
effectiveness of NAIs. Recent meta-analyses of randomised con-
trolled trials (RCT) of seasonal influenza cases demonstrated reduc-
tions in rates of hospitalization, lower respiratory complications, 
and a decreased time to symptom alleviation but were unable to 
confirm or refute an effect of NAIs on more important clinical end 
points such as mortality4,5. A caveat of these studies, which were 
required for licensure of drug in healthy adults, is that they were 
not powered to determine low frequency but critical end points such 
as mortality in a largely healthy adult population. A further meta-
analysis of observational data from pandemic influenza did find 
evidence of a reduction in the risk of mortality when NAIs were 
given to patients hospitalised with influenza6. Some authors have 
criticised it for being subject to a large degree of bias and rejected it 
as a suitable form of evidence with which to formulate policy deci-
sions7,8, though others argue that this evidence strongly supports 
the use of NAI treatment for influenza in hospitalised patients9.
Evidence that has a bearing on death rates is not confined to meas-
urement of mortality alone – there are other sources of relevant 
evidence. Clinical trials show that NAIs have beneficial effects on 
a number of outcomes as described above4–6. The treatment has 
a plausible rationale and it works in vitro and in animal models 
for this zoonosis10. An arguably extreme position is to assume that 
these observations contain no information regarding effective-
ness in preventing the rarer, but more severe outcomes, such as 
death. People who take to heart Bradford Hill’s list of factors that 
should affect the interpretation of data (Box 1), would reject such 
a completely non-theoretical stance. But even within this frame-
work conflicting conclusions may still be drawn, especially when 
inappropriately filtered through the lens of statistical significance. 
Estimation of potentially small effect sizes on rare endpoints is 
often characterised by uncertain and often conflicting evidence and 
many recent studies do conflict with those that support the effec-
tiveness of NAIs11–13. Both an observed reduction and an increase 
in the risk of mortality are therefore potentially consistent with the 
aforementioned evidence. There is thus a compelling case for the 
synthesis of and extrapolation from various forms of evidence in 
order to examine the investment decision facing decision makers.
Previous studies have estimated how cost-effective NAI stock-
piling would be under a range of different pandemic influenza 
scenarios14–19. Stockpiling is generally estimated to be cost- 
effective. However, these studies took observational evidence of 
effectiveness, often from seasonal influenza studies, at face value 
and did not model potential biases that may have led to overestima-
tion of benefits. Moreover, they only examined a limited number 
of specific future scenarios. The results of such cost-effectiveness 
models hinge on the available evidence of effectiveness and it may 
not be immediately clear to decision makers the implications of 
new evidence. We have therefore taken a different approach.
The calculation of the number of deaths from an influenza pan-
demic is simply calculated from a number of relevant variables such 
as the size of the population, the clinical attack rate, and the case 
fatality ratio. The effectiveness of NAIs in terms of relative risks 
can then be used to estimate the potential number of deaths averted 
through their use. A simple model can provide a useful framework 
to synthesise the available evidence while also remaining clear and 
transparent to decision makers. There is a large degree of uncer-
tainty regarding the variables in the model, due to factors such as 
random mutations in the influenza virus, individual behaviour, and 
distribution of NAIs, nevertheless appropriate distributions can be 
specified for each variable and the uncertainty propagated through 
the model to estimate the distribution of possible numbers of deaths 
and resulting QALYs under the stockpiling and no stockpiling 
options. The model presented here exemplifies an approach to deci-
sion making under the types of uncertainty described above using 
a simple, transparent model to assist decision makers and to help 
inform the stockpiling decision.
Methods
Modelling approach
The methods used in this study are founded in normative decision 
theory20,21, which considers what decisions we ought to take, and 
Bayesian statistics. We used a well-established technique based on 
expected utility theory20,21 to model the binary decision to stock-
pile or not to stockpile NAIs. Within this framework, the decision 
simplifies to a question of whether the expected net benefits of the 
stockpiling decision are positive22.
            Amendments from Version 1
We would like to thank the referees, as well as commenters, 
for useful and insightful discussion of our paper. We have 
endeavoured to respond to all referee points. This includes 
additional text in the Introduction and Discussion and we have 
replaced Figure 3 to show the range of decisions to be made 
under different beliefs about NAI effectiveness. In addition, we 
have briefly amended the introduction to reflect the conflicting 
evidence raised by one of the reviewers, and emphasized in the 
discussion that the study is not intended to be proscriptive. 
See referee reports
REVISED
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The net benefit associated with stockpiling was set as the value of 
the deaths averted minus the costs of stockpiling. If the expected 
net benefit of stockpiling is positive then the decision would be to 
stockpile, and if it is negative, not to stockpile.
The value of the deaths averted was modelled as:
  Pop × Prob × CAR × CFR × Hospital × Treated × (1 – θ) × QALY × λ
Firstly, the number of pandemic influenza deaths was calculated 
by multiplying the number of adults in the UK (Pop) by: the prob-
ability of there being a pandemic within the stockpile shelf-life 
(Prop), the clinical attack rate (CAR), and the case fatality ratio 
(CFR). We further multiply by the probability a pandemic influ-
enza death occurred in hospital (Hospital), and the probability one 
of these patients receives NAIs (Treated). The number of deaths 
averted by NAI treatment in this population of NAI-treated adults 
was given by the relative risk reduction in mortality associated with 
NAI treatment (1 – θ). Finally, the value of these deaths averted was 
calculated by multiplying by the quality adjusted life years (QALY) 
associated with each pandemic influenza mortality (QALY), 
and the societal willingness to pay per QALY (λ). This model is 
further explicated in Figure 1.
We considered reductions in mortality among symptomatic adults 
resulting from stockpiling, but did not take into account possible 
additional effects on complications such as pneumonia or that 
community use might reduce complications, hospitalisation, or 
mortality. Only adults were considered on the grounds that NAI 
effectiveness4,6 is less certain in children and to determine if the 
decision to stockpile could be justified on the basis of any benefit 
among adults alone.
Decision modelling is founded in the Bayesian paradigm, which 
was used to evaluate the stockpiling decision for a future pan-
demic with unknown epidemiological variables and unknown 
effectiveness of NAI. A sub-model was specified for each epidemi-
ological variable in the decision model. Data from previous pan-
demics were assumed to be observations from an underlying com-
mon distribution, the parameters of which were estimated using 
these data as described in the following section. The decision was 
then evaluated over posterior predictive distributions for the epi-
demiological parameters. We used a bias corrected effectiveness 
estimate for the effectiveness of NAIs as described below. The 
model was estimated using Markov Chain Monte Carlo (MCMC) 





































Evidence for neuraminidase inhibitors 
 
Reasonably large effect (OR=0.81, 0.71 to 0.94) in reducing mortality in  
hospitalised patients in individual participant data meta-analysis of  
observational evidence6 
 
A previous meta-analysis of observational studies have also shown 
significant reduction in mortality38. 
 
Whether reduction in mortality was mainly attributed to reduction in death 
related to influenza did not seem to have been investigated. Meta-analysis 
of individual participant trial data has shown that reduction in time to  
symptom relief, lower respiratory complications and hospitalisation  
occurred among influenza-infected patients but not among uninfected 
patients4,5. 
 
Early administration of the medication is associated with better clinical  
outcomes4–6, although the temporal relationship between changes in  
influenza viral shedding and clinical outcomes have not been 
well-established39. 
 
Dose-response was observed in some of the animal studies40. 
 
It is biologically plausible that a medication inhibiting the replication of a  
virus will reduce the seriousness of its effects 
 
Evidence for anti-viral activities of the medication is reasonably coherent  
between laboratory studies and clinical observations40. 
 
Randomised controlled trials, while under-powered for outcomes such as  
death and hospitalisation, show reduction in the duration of illness for  
treatment and reduction in symptomatic influenza for prophylaxis4,5. 
 
Prophylactic antiviral medications that reduce cytomegalovirus infection  
also reduce associated death in organ transplant recipients41.
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obviates the need to conduct separate probabilistic sensitivity anal-
yses since the posterior distribution of the net benefits represents 
the uncertainty about future influenza pandemics and NAI effec-
tiveness. The expected net benefits represent the gains or losses 
from stockpiling, on average, given the different distributions for 
the different parameters. Convergence of the MCMC chains was 
assessed by visual inspection of autocorrelation, running mean, and 
trace plots in R.
Data and variables
The data and statistical code are provided with the paper.
Influenza pandemic epidemiology
The data used to estimate the parameters in the model were 
obtained from documents compiled to assess pandemic influenza 
and thus represent the decision maker’s prior knowledge1. The 
shelf-life of oseltamivir, the principle drug comprising the vast 
majority of the NAI stockpile, is ten years23.
The clinical attack rate and case fatality ratios from previous pan-
demics were assumed to be observations from beta distributions. 
Improper non-informative priors with a lower limit of zero were 
assigned to the parameters of these distributions, which were then 
updated with the data from the previous pandemics. We excluded 
the observation of a clinical attack rate of 60% in the 1889–92 
Asiatic flu pandemic as the UK government’s worst case scenario 
is a clinical attack rate of 50%. The probability that a pandemic 
occurs in the shelf life of the stockpile was similarly estimated 
from the data with each decade between 1900 and 2010 as a binary 
observation equal to one if a pandemic occurred in that decade 
and zero otherwise. These binary observations were assumed to be 
observations from a Bernoulli distribution.
Effectiveness of neuraminidase inhibitors
No RCT evidence for the effectiveness of NAIs in reducing the 
risk of mortality in pandemic influenza was available. Too few 
deaths were observed in RCTs of seasonal influenza4. We based 
our effectiveness estimate on a recently published pooled meta- 
analysis of observational, patient-level data from hospitalised 
pandemic influenza virus patients6. We converted the odds ratios 
(OR) for mortality associated with NAIs (irrespective of time 
from onset) provided in the paper into relative risks (RR): 
RR = OR/(1 – p + (p × OR)) where  p is the baseline (approximately 
10%)24. The study was based onhospitalised patients, in order 
to apply the observed relative risk from hospitalised patients to 
the general population considered here, we made two conserva-
tive assumptions. First, we assumed that there would be no dif-
ference in the patients that would be hospitalised and those that 
would remain in the community in a no stockpile and stockpile 
scenarios. This is conservative because community treatment 
will be given earlier, on average, in the course of the disease if it 
can be administered in the community and there is evidence that 
the earlier the treatment is given, the better4–6. Secondly, we assume 
that only deaths occurring in hospital in the non-stockpile sce-
nario would be averted under the counterfactual stockpile scenario. 
A study of mortality in the A/H1N1 2009 pandemic in England, 
found that 92% of deaths (125 of 136 cases studied) occurred in 
hospital25. Assuming that none of these 8% of deaths taking place in 
a non-stockpile scenario would be averted under the counterfactual 
is as conservative as it can be. The logic of our approach is laid out 
in Figure 1.
Bias modelling
In addition to these conservative assumptions regarding the appli-
cation of in-hospital relative risk reductions to a community 
Figure 1. Explanation of the model used to derive the value of the deaths averted due to neuraminidase inhibitor stockpiling.
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population, we also took into account the observational nature of 
the hospital based evidence itself. A number of authors have raised 
this issue in connection with the study used here7,8, although others 
dispute the strength of these criticisms9. We used a method previ-
ously published elsewhere to model bias26. Five reviewers (SIW, 
RJL, YFC, OU, and PJC) who were not associated with the obser-
vational data study independently completed a bias questionnaire 
and provided their beliefs about both additive and proportional 
bias present in the study across a range of domains. The review-
ers were selected on the basis of their experience with obser-
vational data research and its associated biases, with expertise 
in health care and public health research. The median values for 
the mean and standard error of the bias across reviewers were 
used to ‘correct’ the observational evidence26. The method for bias 
modelling used here was originally intended for individual stud-
ies so that they could be adjusted prior to an evidence synthesis26. 
This method has been applied here since the study in question 
is an individual patient pooled meta-analysis, analysed using a 
similar method to that any single study would use, except that the 
data originate from multiple locations and are of varying quality. 
The reviewers considered this an additional source of uncertainty 
when evaluating the quality and potential for bias.
QALY losses
The distribution for the average age associated with an influenza 
death in previous pandemics was assumed to be drawn from a 
scaled Beta distribution with an upper limit of 81.5, which is the 
UK life expectancy at birth. The parameters of this distribution 
were then estimated from data; the average ages of influenza deaths 
from prior pandemics were 27 (1918), 65 (1957), 62 (1968), and 
45 (2009)25,27,28, no data were available from the 1889–92 pandemic. 
To estimate QALYs lost due to an influenza death, the remaining 
life expectancy was calculated by differencing the average age at 
death from the UK life expectancy at birth (i.e. 81.5 years)24. These 
years were weighted by the average QALY weight for a person aged 
over 45 of 0.825, and then discounted at the rate of 3.5% per annum 
as recommended by the National Institute for Health and Care 
Excellence (NICE)29.
Other parameters
We also estimated the probability a pandemic influenza death 
occurred in hospital using data on 2009 pandemic influenza 
deaths25. We further considered a number of scenarios for the 
distribution of NAIs and the proportion of symptomatic pan-
demic influenza cases that would receive the drug. Our base case 
was 100%, however we also considered the decisions that would 
be made in the range of 0% to 100% in a deterministic sensitiv-
ity analysis – the value of the deaths averted was multiplied by a 
number between zero and one. The cost of stockpiling was assumed 
fixed at £560 million ($860m, €750m) and was based on the figures 
quoted in the above mentioned Select Committee hearings3. 
We considered the adult population of the UK, which was 50.5 
million in 201530. The willingness to pay per QALY was selected 
as £20,000/QALY ($31,000/QALY) for the base case analysis, the 
lower end of the range (£20,000-£30,000/QALY; $31,000–$45,000/
QALY) specified by NICE as being cost-effective29. We exam-
ined the decision that would be made under a range of willing-
ness to pay per QALY values of £5,000/QALY ($7,500/QALY) to 
£30,000/QALY ($45,000/QALY).
Results
Summary of estimated parameters
Table 1 shows the posterior mean and 95% credible intervals for 
the parameters in the model. Using data from previous influenza 
pandemics, mean values (95% credible intervals) were as follows: 
clinical attack rate 23.8% (5.2%, 50.6%), case fatality ratio 0.7% 
(0.0%, 3.0%), and probability of experiencing a pandemic within 
a decade 38.5% (15.3%, 64.9%). The expected value for the mean 
QALY losses associated with influenza mortality was 15.2 (5.7, 
20.9). The proportion of pandemic influenza deaths that occurred in 
hospitalised patients was 91.9% (86.9%, 95.8%).
The observed relative risk was 0.83 (95% confidence interval: 
0.71, 0.94) and the bias corrected relative risk was estimated as 
0.89 (0.71, 1.07). The principle sources of bias identified by the 
reviewers were selection bias, due to a lack of randomisation, the 
possibility that studies with a positive finding may have been more 
likely to volunteer their data for the meta-analysis, and attrition 
bias. Not all reviewers were in agreement about the overall effects 
of bias, but the median response was that there was an overestima-
tion of treatment benefit.
Main results
Table 2 shows the results from various scenarios considered. The 








Willingness to pay per 
QALY £20,000/QALY 29




Adult Population 50.5 million 30
CARb 23.3% (5.2%, 50.6%) 1
CFRb 0.72% (0.01%, 2.97%) 1
QALY loss, mortality 15.2 (5.7, 21.0) 25,27,28,42,43 
Proportion of pandemic 















CAR = clinical attack rate; CFR = case fatality ratio. Probabilities expressed 
as %.
aAssumed to be fixed.
bSee Appendix A for derivation.
cRelative risks converted from odds ratios (0.81, 95% CI: 0.70, 0.93) using a 
baseline risk of mortality of 10%19.
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positive, which was caused by the very large number of deaths, 
many of which may be prevented by stockpiling, in the unlikely 
event of a severe pandemic. This can be seen in the long tail on the 
left of the distribution in Figure 2.
Figure 3 shows the decision under a range values for the 
effectiveness of NAIs, the percentage of hospitalised, sympto-
matic adults who would receive NAIs and willingness to pay per 
QALY threshold. If 100% of hospitalised, symptomatic adults 
with influenza received NAIs then the decision would be to stock-
pile as long as our threshold willingness to pay per QALY was 
greater than £11,116/QALY under our ‘bias corrected’ effective-
ness estimate. When only 50% of hospitalised, symptomatic adults 
receive NAIs this threshold increases to £22,232/QALY, which 
would still be considered cost-effective in the range considered 
by NICE. The minimum percentage of hospitalised, symptomatic 
adults with influenza that would need to receive NAIs for the 
decision to be to stockpile at a threshold willingness to pay of 
£20,000/QALY is 56%. Conversely, when the proportions of 
hospitalised, symptomatic adults who receive NAIs is 50%, 75%, 
or 100%, the minimum value for the relative risk of mortality asso-
ciated with NAIs required for the intervention to be considered 





This zip folder contains raw data behind the findings presented. 

















1 100 444 (-808, 8,383) -560 Stockpile
2 70 143 (-734, 5,700) -560 Stockpile
3 50 -58 (-684, 3,911) -560
Not 
Stockpile
4 30 -259 (-634, 2,123) -560
Not 
Stockpile
The decision is to stockpile if the expected net benefit is greater than 
zero and not to stockpile otherwise. The willingness to pay per QALY 
is £20,000/QALY in all scenarios.
Figure 2. Posterior distribution of the loss function for stockpiling NAIs showing the mean and median values of the distribution along 
with the decision threshold for stockpiling. The x-axis has been truncated at £4·5b.
£444 million ($668 million). The decision would be therefore to 
stockpile NAIs. Figure 2 shows the posterior distribution of net 
benefits. The mean number of deaths averted was 3,218. There was 
a 77% probability that the benefits were negative implying that no 
pandemic occurred, an insufficiently large pandemic occurred, or 
NAIs were not effective enough to justify the stockpile. The median 
net benefit was £-560 million in each case as in the majority of 
scenarios no pandemic occurred and there was only the net cost 
of the stockpile. Nevertheless, the mean estimated net benefit was 
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Figure 3. Stockpiling decisions that would be made under a range of different values for the effectiveness of NAIs, the percentage 
of hospitalised, symptomatic adults  that would receive NAIs, and  thresholds  for willingness  to pay per QALY. The lines represent 
thresholds for decision makers. For any point inside the region bounded by a given line the decision maker should stockpile and conversely 
any point outside that region the decision maker should not stockpile. 
Discussion
This study has found that the available evidence suggests that 
stockpiling NAIs for pandemic influenza is rational under a range 
of assumptions. Many of these assumptions are conservative, such 
as no reduction in adverse clinical outcomes other than mortality, 
no benefit in patients who would not have been hospitalised had 
there been no stockpile, and no effect in children. However, this 
decision required at least 56% of the influenza patients who would 
have died without a stockpile to receive NAIs if the threshold 
willingness to pay was £20,000/QALY. In the 2009 pandemic, 
64% of hospitalised patients received NAIs6, and in the United 
Kingdom specifically this proportion was 75%31, suggesting that 
56% is achievable, and that therefore, stockpiling is supported 
by the available evidence.
This paper is predicated on the purchase of a stockpile large enough 
to treat a large proportion of the population (80% in the UK) in the 
community and in hospital with NAIs. This may well be the correct 
strategy if new evidence emerges that community-based treatment 
reduces either complications, hospitalisations or mortality. Further 
research will be required; indeed, the Bayesian decision analy-
sis used here can be extended to consider how much to stockpile 
rather than simply whether to stockpile. However, if the evidence 
base were to remain limited to mortality reductions in hospitalised 
patients, or if the societal willingness to pay per QALY was low, 
as it may be in many resource poor settings, a ‘hospital-treatment 
only’ policy might be considered. This would reduce the cost of 
the stockpile significantly. For example, in the 2009 pandemic only 
0.5% of symptomatic cases were hospitalised32, these patients would 
require far fewer doses than the 1.16 million courses (at a minimum) 
of NAIs dispensed in the 2009 pandemic33. For a population of 
50.5 million adults with a CAR of 25%, a hospitalisation probability 
of 0.5% would lead to only approximately 60,000 admissions. The 
evidence also suggests that more timely treatment of NAIs (within 
two days of symptom onset) is more effective than treatment at 
any point6, which would suggest that the effectiveness of NAIs 
could be more favourable than modelled under the stockpiling 
policy. In all cases the decision would remain to stockpile NAIs.
Our conclusions are in line with the decision that would be made on 
the basis of cost-effectiveness evidence from previous studies14–19. 
However, our study does not take observational evidence at face 
value, but ‘downgrades’ it, thereby yielding a reduced estimate 
of effectiveness and wider credible limits. We have calculated the 
distribution of possible deaths from pandemic influenza using a 
relatively simple mathematical model and then ‘averaged’ over 
the distributions of the variables rather than examining cost- 
effectiveness on a scenario-by-scenario basis. This approach is 
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intuitively simple and is aimed to provide correct inferences using 
a simple logical framework for the synthesis of the commonly 
available evidence in order to assist decision makers with a com-
plex decision. The model allows the logical basis of the decision 
to be ‘reverse engineered’, allowing the decision to be critiqued 
within the framework established by the model. We note though 
that many people are highly sceptical about the benefits of 
NAIs. This study is not intended to be proscriptive. As Figure 3 
illustrates, a decision maker with a highly sceptical belief about 
NAI effectiveness should not stockpile.
Obtaining an estimate for the bias in any particular study, or con-
solidated group of studies, is clearly an uncertain undertaking. 
There is an evidence base on bias arising from meta-regressions or 
other analyses comparing the results of imperfect studies to those 
of a ‘gold standard’. A recent Cochrane review comparing treat-
ment effects reported in observational studies as compared to RCTs 
found that, “on average, there is little evidence for significant effect 
estimate differences between observational studies and RCTs...”34 
It is not surprising, given the considerable uncertainties surround-
ing the meta-analysis cited here, that the differences between the 
reported effects and our bias corrected effect resembles the dif-
ferences in empirical studies comparing observational studies and 
RCTs34–36.
We acknowledge weaknesses in our study. The only outcome con-
sidered in the analyses was mortality. Adverse events caused by 
NAIs may also generate increased costs and hence reduced benefit. 
For example, a review of clinical trial evidence of NAIs found an 
increased risk of nausea and vomiting associated with treatment4. 
The authors also reported a possible increase in the risk of psy-
chiatric adverse events. However, this only reached statistical sig-
nificance in exploratory analyses including a supra-licence dose 
and off-treatment periods. A more recent meta-analysis based on 
individual-level patient data of clinical trials focusing on licensed 
dose only found no such effects, but the number of events was 
small5. Neuraminidase inhibitors may also have protective effects 
against some adverse events such as cardiac events, and may reduce 
the risk of influenza-associated pneumonia and hospitalisation4,5. 
The benefit of treatment is unlikely to be grossly over-estimated and 
is likely to be under-estimated given our conservative assumptions. 
We have also not considered potential effects on children or from 
reductions in complications, hospitalisations or mortality that might 
be associated with community-based treatment, or any benefit aris-
ing from changing disease dynamics and reduced transmission; 
nor have we considered wider societal effects, such as productivity 
gains, reduced community transmission, and the value placed on a 
stockpile for a potentially risk averse population, all of which may 
increase the benefits of stockpiling.
We note that our analysis is focussed on the United Kingdom but 
that it may be of use to other countries. The model for the ben-
efits of NAIs can be simply applied to new contexts. However, the 
determination of the costs of the stockpile remains difficult. 
The costs depend on the treatment strategy planned for a given 
country and any price negotiations between the manufacturer and 
the government. A useful tool in this context is the ‘headroom’ 
method that asks instead what the maximum amount a decision 
maker should be willing to pay for an intervention, given a will-
ingness to pay per unit benefit. This is a useful direction for future 
research.
We have assumed independence between the clinical attack rate and 
case fatality ratio, as well as other variables, however there is some 
evidence to suggest that they could be correlated37. Nevertheless, 
the data are admittedly scant, and it is expected that this is a neutral 
assumption. Of course, if they are positively correlated then our 
conclusions become more conservative.
Our model examines the decision in the abstract and does not 
concern itself with externalities such as the possibility that avail-
ability of the drug will affect attitudes and hinder the effort to 
contain the spread of the disease, or that resistance to antivirals 
may develop. Nor have we considered the sensitivity of clinical 
diagnosis of influenza in identifying true positives or the costs and 
logistics of establishing a distribution process for the NAIs. The 
propensity to consult is also an important factor that may have 
affect the proportion of true positives, which in turn may have 
a bearing on the use of a stockpile if used on a “first come, first 
served” basis. Further research is required to optimize distribution 
and behaviour during a pandemic to ensure the cost-effectiveness 
of the stockpiling.
Conclusions
Taking into account the existing evidence on pandemic influenza 
and the effectiveness of NAIs the decision should be to stockpile, 
provided a utilitarian decision-making framework is used of mini-
mising expected losses and hence maximising expected benefits.
Data availability
The data used to estimate the parameters in the model were obtained 
from documents compiled to assess pandemic influenza and thus 
represent the decision maker’s prior knowledge1.
F1000Research: Dataset 1. Raw data of ‘stockpiling neurami-
nidase inhibitors for pandemic influenza usage’, 10.5256/
f1000research.9414.d13265344.
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As stated above, the reader would be well served with an additional figure similar to Figure
3, but plotting QALY threshold against mean NAI effectiveness. In my shallow
experimentation with the author's model, it looks like at 20,000 GBP / QALY, NAIs cease




The suggestions made below I think might improve the article however I think the authors can best
judge whether the additional effort and added complexity would be worthwhile or would be too
diverting.
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I commend the authors for including the model code in the Appendix, I managed to run this code
with relatively little effort.
The methodology of using expert opinion to mitigate potential bias in the studies estimating
NAI effectiveness is a practical measure that is probably worthwhile. Some additional detail
on the process would be appreciated. For example: how were assessors selected? How




In the discussion it could be noted that in a future pandemic with a large CAR or CFR, the
proportion of severe cases receiving hospital care and the level of care are likely to be
lower, simple due to hospitals being overwhelmed. The estimates of proportion of
deaths occurring in hospital are from the 2009 pandemic which was very mild.
 
If NAIs have any effect in preventing further transmission, e.g if they shorten the period of
viral shedding, then mass administration of antivirals may reduce the overall attack rate and
consequent mortality even if NAIs are not effective for mortality reduction of severe





The CAR and CFR parameters used in the model are for a pandemic without NAI usage.
Given that NAIs were used in the 2009 pandemic, should the CAR and CFR estimates for
2009 be included along side those of previous pandemics? If the 2009 CAR and CFR
estimates are for example based on global data where NAI usage might be negligible









In the Appendix page 4 there is a citation [20] that isn't given in a reference list.
This has been amended.
 
In the last sentence of the 3rd paragraph, the RR derived based on the OR and 10%
mortality is stated as 0.89. This is the same as the bias-corrected RR given in the next
paragraph. Is this intentional? Or should it be the RR value based on the OR and 10%




The R / BUGS code in the Appendix worked almost without alteration. I found that I had to:
Install BUGS (OpenBGUS).
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Hoist the npv function to the top.
Remove the codaPkg=TRUE setting to obtain a result object.
(also the "obs" and "qaly" values appear to be dead code)
If F1000 allows additional appendix files this could be supplied as an additional plain ASCII





I can't find the support for the n_hosp data value of 136. The tot_hosp value of 125 appears
in the Donaldson BMJ paper. That paper gives 138 for the total number of confirmed deaths
due to pandemic influenza.
This typo has been amended.
 As stated in the article.Competing Interests:
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This is a well-designed, carefully executed and documented study, that provides important insights
into the cost-effectiveness of national stockpiles of neuraminidase inhibitors to be used during
influenza pandemics. 
The analysis is relying on a number of key assumptions, such as the effectiveness of NAI antivirals
against mortality due to influenza, the probability of a pandemic occurring during the shelf life of the
stockpile and the proportion of pandemic influenza deaths occurring in hospital. Many of these
assumptions are based on a limited or controversial evidence base, however the authors
acknowledge and address most of these limitations.
The assumption that most pandemic deaths occur in hospitals, is based on the observation during
the 2009 pandemic in the UK, however in many countries, already during severe influenza
A(H3N2) epidemics, and during many previous pandemics, the majority of deaths are likely to
occur in the community, outside of hospitals. It is confusing that the authors compare the costs of a
population wide (80%) stockpile with the estimated benefits on hospital mortality only. Although
this is discussed in the second paragraph of discussion, it would be helpful to see an analysis or









It is likely that such an analysis would be useful for other countries than UK. Please discuss briefly
the limitations of this approach and these assumptions, when replicating the study in other settings
(such as differences in societal willingness to pay per QALY).
We have amended the discussion to reflect this.
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 In Box 1. the two columns are not aligned when viewing as a pop-up on MS Internet Explorer.
This is an issue for the journal.
In Figure 1. the references to UK, and the national pandemic flu service are not helpful and distract
from the more general main message of this figure.
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